GlassScriptPhysician profile
Aisha F Sheerin
NPI 1588184881
$1,168.76
in general payments reported to CMS, 2019-2025
19 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $159 · 2023: $502 · 2024: $340 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $207.86 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $158.55 | 2023-2025 | Airsupra, Lokelma, Breztri |
| Pfizer INC. | $144.47 | 2023-2025 | |
| Neurelis, INC. | $73.35 | 2023-2024 | Valtoco |
| Abbvie INC. | $73.01 | 2023-2024 | Teflaro |
| Janssen Scientific Affairs, LLC | $66.50 | 2023 | Xarelto |
| Novo Nordisk INC | $65.41 | 2023-2024 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $54.33 | 2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.10 | 2022 | |
| Baxter Healthcare | $41.09 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $37.45 | 2024 | Opsumit |
| Abiomed | $33.84 | 2023-2024 | Impella |
| Scpharmaceuticals INC. | $28.68 | 2025 | |
| Amgen INC. | $27.08 | 2025 | |
| Grifols USA, LLC | $23.63 | 2023 | Gamunex-C |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.14 | 2023 | |
| Glaxosmithkline, LLC. | $20.58 | 2025 | Nucala |
| Lexicon Pharmaceuticals, INC. | $19.87 | 2024 | Inpefa |
| Biomerieux INC | $19.82 | 2023 | Biofire Blood Culture Identification 2 (Bcid2) Panel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Sheerin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.